This is a working overview of PPARδ agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-03. Anything still debated is marked as such rather than presented as settled.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human therapeutic use | No marketing authorization identified in major jurisdictions. |
| Anti-doping class | PPARδ agonist; hormone and metabolic modulators | Listed on the WADA Prohibited List. |
| Common test matrix | Urine | Also blood and tissue in research settings. |
| Typical analytical method | LC-MS/MS | Targets parent compound and metabolites. |
| Major safety signal | Tumor findings in rodents | Human relevance not established; limited human data. |
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
SPR curves usually show a strong minimum. With the use of a combined chromium-gold film or other carefully chosen material combinations a sharp resonance maximum can be observed when exciting a surface plasmon in the Kretschmann configuration. This may be useful in sensors applications where a strong and sharp resonance above noise is required and less heat is desired at the surface.
13 March – Five people are taken to hospital for treatment after a bus crashes into a high rise block of flats in Paisley, Glasgow. 14 March – The Scottish Parliament Corporate Body finds Michael Matheson in breach of the Ministerial Code over his £11,000 iPad bill. Mountaineer Anna Wells becomes the first woman to reach the top of all of Scotland's 282 Munros in one winter season. 15 March – Following trial and conviction at the High Court in Glasgow, double murderer Peter Duffy is sentenced to at least 30 years in prison for the murder of his wife, Emma Baillie, and brother, John-Paul Duffy, in separate incidents in Coatbridge in 2022. 17 March – HMP Kilmarnock becomes the first privately run prison in Scotland to pass into the ownership of the Scottish Prison Service after its contract with Serco comes to an end. 19 March – Scottish Prison Service director Allister Purdie gives evidence to the Scottish COVID-19 Inquiry, and apologises to the family of Callum Inglis, who died at Addiewell Prison during the pandemic, after his family learned of the death through word of mouth before they were told formally by prison authorities. 21 March – The Scottish Parliamentary Corporate Body confirms that members of Scottish Parliament staff will no longer be allowed to wear rainbow lanyards, or any other badge or jewellery associated with social issues, while at Holyrood. The Wildlife Management and Muirburn (Scotland) Bill passes its final vote in the Scottish Parliament.
A fascia (; pl.: fasciae or fascias; adjective fascial; from Latin fascia 'band') is a generic term for macroscopic membranous bodily structures. Fasciae are classified as superficial, visceral or deep, and further designated according to their anatomical location. The knowledge of fascial structures is essential in surgery, as they create borders for infectious processes (for example Psoas abscess) and haematoma. An increase in pressure may result in a compartment syndrome, where a prompt fasciotomy may be necessary. For this reason, profound descriptions of fascial structures are available in anatomical literature from the 19th century.
Thus, CK enhances skeletal, cardiac, and smooth muscle contractility, and is involved in the generation of blood pressure. Further, the ADP-scavenging action of creatine kinase has been implicated in bleeding disorders: persons with highly elevated plasma CK could be prone to major bleeding.
Sources: en.wikipedia.org
== See also == Buried penis Castration anxiety Crotch (in clothing) – a pouch-shaped area built to accommodate a penis and scrotum Micropenis Penile enlargement Penis removal Phallic architecture Phallus – an object or image that resembles a penis Preputioplasty – an operation performed to facilitate retraction of the foreskin Stunt cock – a substitute penis used for filmmaking
Claire Darke, former mayor of Wolverhampton and a longtime Labour councillor, resigns from the Labour Party, citing disillusionment with its direction under Keir Starmer. She specifically criticizes the party's stance on austerity and its "morally wrong" position on Gaza, which she sees as neglecting the suffering of the Palestinian people. 25 June – Emperor Naruhito and Empress Masako of Japan begin their state visit to the United Kingdom. 2024 United Kingdom general election date betting controversy: The Conservative Party withdraws its support for Craig Williams and Laura Saunders as election candidates. Cabinet minister Alister Jack, who previously said he had won £2,100 by betting on the date of the election, then said he was joking, issues a statement in which he says he did not place a bet on the election. Russell George, the Senedd member for Montgomeryshire, becomes the fifth Conservative politician to be investigated by the Gambling Commission for election betting. The Metropolitan Police confirms that the Gambling Commission are investigating a further five police officers for placing bets on the date of the election. Labour suspends Kevin Craig, their candidate for Central Suffolk and North Ipswich, after the Gambling Commission launches an unrelated investigation into him for placing a bet against himself losing in his constituency. LBC's Nick Ferrari moderates an immigration policy debate between Home Secretary James Cleverly and Shadow Home Secretary Yvette Cooper.
Plutonium-238 has a half-life of 87.74 years. It emits a large amount of thermal energy with low levels of both gamma rays/photons and neutrons. Being an alpha emitter, it combines high energy radiation with low penetration and thereby requires minimal shielding. A sheet of paper can be used to shield against the alpha particles from 238Pu. One kilogram of the isotope generates about 570 watts of heat. These characteristics make it well-suited for electrical power generation for devices that must function without direct maintenance for timescales approximating a human lifetime. It is therefore used in radioisotope thermoelectric generators and radioisotope heater units such as those in the Cassini, Voyager, Galileo and New Horizons space probes, and the Curiosity and Perseverance (Mars 2020) Mars rovers. The twin Voyager spacecraft were launched in 1977, each containing a 500 watt plutonium power source. Over 30 years later, each source still produces about 300 watts which allows limited operation of each spacecraft. An earlier version of the same technology powered five Apollo Lunar Surface Experiment Packages, starting with Apollo 12 in 1969. 238Pu has also been used successfully to power artificial heart pacemakers, to reduce the risk of repeated surgery. It has been largely replaced by lithium-based primary cells, but as of 2003 there were somewhere between 50 and 100 plutonium-powered pacemakers still implanted and functioning in living patients in the United States. By the end of 2007, the number of plutonium-powered pacemakers was reported to be down to just nine.
Sources: en.wikipedia.org
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.
It is classified as a PPARδ agonist on the WADA Prohibited List. Anti-doping laboratories can detect it and its metabolites in urine. Its use is banned in competition and usually out of competition.
Rodent studies reported increased tumor incidence at multiple sites. The human relevance remains uncertain, but the findings contributed to discontinuation of development. No long-term human cancer data are available.
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.